This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of BGB324 in combination with pembrolizumab in up to 56 patients with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The study will utilise an extension of Simon's 2-stage design. The primary objective is objective response rate.